{
    "2019-12-06": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Pharma Stock Roundup: FDA Updates for RHHBY, AZN, MRK, No Asbestos in Talc Says JNJ",
                "features": {
                    "keywords": [
                        "FDA",
                        "Updates",
                        "RHHBY",
                        "AZN",
                        "MRK",
                        "Asbestos",
                        "Talc",
                        "JNJ"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-06-20",
                "original_text": "Glaxo Files NDA for Fostemsavir for Heavily Pre-Treated HIV",
                "features": {
                    "keywords": [
                        "Glaxo",
                        "NDA",
                        "Fostemsavir",
                        "HIV"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-08-14",
                "original_text": "Acquisition Rumors Arenâ€™t the Only Thing Moving Amarin Stock",
                "features": {
                    "keywords": [
                        "Acquisition",
                        "Rumors",
                        "Amarin",
                        "Stock"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-10-22",
                "original_text": "After Biogen's big Alzheimer's drug data reveal, observers remain divided",
                "features": {
                    "keywords": [
                        "Biogen",
                        "Alzheimer's",
                        "drug",
                        "data",
                        "reveal",
                        "observers",
                        "divided"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}